



Regulation of neuronal fate specification and connectivity of the thalamic reticular nucleus by the *Ascl1-Is11* transcriptional cascade

Quy-Hoai Nguyen¹ · Hong-Nhung Tran¹ · Yongsu Jeong¹

Received: 28 June 2024 / Revised: 21 October 2024 / Accepted: 19 November 2024
© The Author(s) 2024

Abstract

The thalamic reticular nucleus (TRN) is an anatomical and functional hub that modulates the flow of information between the cerebral cortex and thalamus, and its dysfunction has been linked to sensory disturbance and multiple behavioral disorders. Therefore, understanding how TRN neurons differentiate and establish connectivity is crucial to clarify the basics of TRN functions. Here, we showed that the regulatory cascade of the transcription factors *Ascl1* and *Is11* promotes the fate of TRN neurons and concomitantly represses the fate of non-TRN prethalamic neurons. Furthermore, we found that this cascade is necessary for the correct development of the two main axonal connections, thalamo-cortical projections and prethalamo-thalamic projections. Notably, the disruption of prethalamo-thalamic axons can cause the pathfinding defects of thalamo-cortical axons in the thalamus. Finally, forced *Is11* expression can rescue disruption of cell fate specification and prethalamo-thalamic projections in in vitro primary cultures of *Ascl1*-deficient TRN neurons, indicating that *Is11* is an essential mediator of *Ascl1* function in TRN development. Together, our findings provide insights into the molecular mechanisms for TRN neuron differentiation and circuit formation.

Keywords Diencephalon · Transcription factor · Mouse · Embryo · Differentiation

Introduction

Mounting evidence points to a disruption of functional connectivity between the cerebral cortex and thalamus in the pathogenesis of psychiatric disorders, including autism spectrum disorder, bipolar disorder, major depressive disorder, and schizophrenia [1–4]. In this context, the thalamic reticular nucleus (TRN) is particularly noteworthy because it influences cortico-thalamic and thalamo-cortical communications [5]. The TRN consists of GABAergic neurons and functions as an ideal hub, as all of the axons connecting the cortex and thalamus pass through the TRN, which receives excitatory inputs from cortico-thalamic and thalamo-cortical neurons and sends inhibitory outputs to the thalamus [6]. The TRN plays important roles in regulating sensory attention, sleep, arousal, and cognition [5, 7–10],

and abnormalities in the TRN may cause behavioral deficits in individuals with autism, attention deficit hyperactivity disorder (ADHD), and schizophrenia [2, 3, 11]. Despite the functional importance of the TRN, few studies have investigated the molecular mechanisms underlying the development of the TRN with regard to neuronal differentiation and connectivity during embryogenesis.

The positioning of the TRN between the thalamus and telencephalon is crucial to an important aspect of its principal function. The TRN surrounds most of the rostrolateral surface of the thalamus and originates in proliferating progenitor cells in the alar plate of the third prosomere (p3), a diencephalic segment, which gives rise to the prethalamus [12]. Although the TRN shares a common developmental origin with other prethalamic nuclei, such as the zona incerta (ZI) and the ventral lateral geniculate nucleus (vLG), it acquires different functions and connectivity from the remainder of the prethalamus, which constitutes widespread connectivity in the forebrain, midbrain, and hindbrain [13–15]. During the patterning phase of the diencephalon, prethalamic formation is influenced by dorsoventral interactions of *Wnts* and *Shh* [16–18] and by anteroposterior interactions of *Six3*, *Fezf*, *Irx*, and *Otx* [19–22]. Inactivation of

✉ Yongsu Jeong
yongsu@khu.ac.kr

¹ Department of Genetics and Biotechnology, College of Life Sciences, Graduate School of Biotechnology, Kyung Hee University, Yongin 17104, Republic of Korea

Olig2 leads to reduced prethalamus and a change in the fate of *Olig2*⁺ prethalamus to rostrally adjacent thalamic eminence [23]. Unlike well-studied brain structures such as the cortex and thalamus, little is known about how individual progenitor cells differentiate to populate distinct prethalamic nuclei, how the prethalamic nuclear identity is established, and how prethalamic nuclei undergo further functional differentiation, including axon projection.

In this study, we present evidence that the transcriptional cascade of the *Ascl1* and *Isl1* transcription factors orchestrates cell fate specification and axonal circuit formation in the TRN. The LIM homeobox gene *Isl1* is necessary for motor neuron and interneuron differentiation in the neural tube [24] and for retinal ganglion cell differentiation [25]. *Isl1* is indispensable for melanocortin neuron cell fate and for estrogen receptor- α expression [26, 27]. In the telencephalon, *Isl1* plays crucial roles in the formation of the striato-nigral pathway [28–30]. The proneural bHLH factor *Ascl1* influences various developmental processes, including cell fate specification, differentiation and migration [31]. *Ascl1* plays important roles in conferring neuronal identity in the spinal cord [32, 33], hypothalamus [34], and telencephalon [35, 36]. A previous study demonstrated that loss of *Ascl1* results in defective pathfinding of thalamo-cortical axons (TCAs) accompanied by defective differentiation of brain regions that lie along the TCA pathway [37]. Herein, we focused on the TRN and examined whether the *Ascl1* and *Isl1* transcription factors influence prethalamus subdomain-specific cell fate decisions and axon circuitry during embryonic development.

Results

Isl1 is required for promoting TRN cell identity and repressing non-TRN prethalamic cell fates in the TRN


To explore whether *Isl1* is required for prethalamic differentiation, we conditionally inactivated *Isl1* expression by crossing an *Isl1*^{F/F} mouse line, in which the homeodomain (exon 4) is flanked by loxP sites [38], with a *Dlx5/6-Cre* mouse line that drives Cre-mediated recombination in the ventral forebrain [39]. During embryogenesis, *Isl1* is principally expressed in the TRN, a prethalamic derivative (Fig. S1A–C). In *Dlx5/6-Cre; Isl1*^{F/F} embryos, *Isl1* staining was almost completely lost in the prethalamus as well as in other forebrain regions (Fig. S1D–F). We first analyzed the effects of *Isl1* loss on prethalamic differentiation by staining for *Hes5* and *Sox2*, which mark proliferative progenitors, as well as for the postmitotic neuronal markers *Elavl3/4* (*HuC/D*). At E12.5, *Hes5/Sox2* and *HuC/D*, which exhibit mutually exclusive expression, were similarly expressed

Fig. 1 TRN neuronal identity is dependent on *Isl1* function. **(Top)** Schematic showing the wild-type anatomy of the prethalamus. **(A–N)** In situ hybridization of prethalamic markers on control (*Dlx5/6-Cre; Isl1*^{F/+}) and mutant (*Dlx5/6-Cre; Isl1*^{F/F}) coronal sections. The red boxed areas are magnified as indicated. The patterns of gene expression in the prethalamus at E14.5 were similar to those at E16.5. **(A–B)** *Dlx1* was normally expressed in all prethalamic nuclei, including the rZI, TRN, and vLG, as well as the central diencephalic organizer zli. *Dlx1* expression in the TRN of control embryos was high (A2, B2), while *Isl1*-deficient embryos lost *Dlx1* expression specifically in the TRN but not in the vLG, rZI or zli (A4, B4). **(C–D)** Within the prethalamus of control embryos, *Meis2* expression was limited to the TRN (C2, D2). Loss of *Isl1* resulted in the abrogation of *Meis2* expression (C4, D4). **(E–L)** *Arx*, *Pax6*, and *Lhx1* were normally expressed in the rZI, zli, and rostroventral parts of the vLG but were not detectable in the TRN. *Lhx5* is also weakly expressed in the rZI, zli, and vLG but not in the TRN. In the absence of *Isl1* function, the expression of these genes was largely unaffected in the rZI, zli, and vLG but was ectopically induced in the TRN. **(M, N)** A GABAergic neuronal marker *Gad1* was similarly expressed in control and *Isl1* mutants. **(O)** Quantification of in situ hybridization. The pixel intensity values of TRN or vLG were grouped and averaged from three different sections per embryo. ($n=5$ embryos; Student's *t*-test; ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$) **(P)** A schematic diagram indicating that *Dlx1*⁺*Meis2*⁺ TRN cells lose their identity and instead acquire molecular features of the remainder of the prethalamus. Cx, cortex; Hyp, hypothalamus; Pt, prethalamus; rZI, rostral zona incerta; Th, thalamus; TRN, thalamic reticular nucleus; vLG, ventral lateral geniculate nucleus; zli, zona limitans intrathalamica. Scale bar, 200 μ m

in control (*Dlx5/6-Cre; Isl1*^{F/+}) and *Isl1*-deficient embryos (Fig. S2A–D). We next examined early patterning in the conditional mutants by analyzing the distribution of *Ascl1*, *Gsx1/2*, *Helt*, *Olig2*, and *Nkx2.2*, which are specifically expressed in prethalamic progenitors. None of these markers were significantly altered in *Dlx5/6-Cre; Isl1*^{F/F} embryos compared to control littermates (Fig. S2E–J).

Prethalamic progenitors differentiate and populate into heterogeneous nuclear groups, including the TRN, zona incerta (ZI), and ventral lateral geniculate nucleus (vLG). At E14.5 and E16.5, these three major nuclei can be identified by postmitotic regional markers [40, 41]. The TRN consists of a sheet of cells surrounded by the rostral ZI (rZI), vLG and zona limitans intrathalamica (zli) and can be identified by staining for *Dlx1* and *Meis2* (Fig. 1A2, B2, C2, D2). *Dlx1* was also expressed in the rZI, vLG, and zli (Fig. 1A2, B2), while *Meis2* was mainly detected in the TRN (Fig. 1C2, D2). *Arx*, *Pax6*, and *Lhx1/5* were expressed in the rZI and vLG at distinct levels (Fig. 1E2, F2, G2, H2, I2, J2, K2, L2). *Arx* and *Lhx1/5* were also detected in the zli, and *Pax6* expression was observed in the rostral half of the zli [40–42] (Fig. 1E2, F2, G2, H2, I2, J2, K2, L2). In contrast, the TRN does not express *Arx*, *Pax6*, or *Lhx1/5* at detectable levels (Fig. 1E2, F2, G2, H2, I2, J2, K2, L2; Fig. S3). In the absence of *Isl1*, compared with that in controls, *Dlx1* was similarly expressed in the rZI, vLG, and zli, but *Dlx1* expression was undetectable in the TRN at E14.5 and E16.5 (Fig. 1A4, B4). In addition, *Meis2* expression was almost completely absent

Figure 1



in the TRN of *Dlx5/6-Cre; Isl1^{F/F}* embryos (Fig. 1C4, D4). Concomitantly, the loss of *Isl1* function led to the ectopic induction of *Arx*, *Pax6* and *Lhx1/5* in the TRN (Fig. 1E4, F4, G4, H4, I4, J4, K4, L4; Fig. S3), suggesting the derepression of TRN-depleted genes in the TRN in the absence of *Isl1*. We further examined the mRNA level of *Gad1*, which encodes the GABA synthetic enzyme glutamate decarboxylase. Loss of *Isl1* did not result in significant changes in *Gad1* expression in the prethalamic regions (Fig. 1M4, N4), indicating that the prethalamic complex maintains a GABAergic neurotransmitter phenotype in the absence of *Isl1*, but the neuronal subtype composition in the complex was altered. Therefore, these observations demonstrate that *Isl1* is required for the acquisition of TRN identity and for suppressing non-TRN prethalamic neuronal fates in the TRN.


Isl1 is required for normal TCA navigation in the TRN

As the TRN is a diencephalic contingent that TCAs first encounter and cross, we considered potentially important factors of the TRN in normal TCA projection. Therefore, we determined the effect of *Isl1* deletion on the progression and navigation of thalamic axons as they cross the TRN. To specifically label TCAs in the developing forebrain, we crossed the *Dlx5/6-Cre; Isl1^F* allele with the *Gbx2^{GFP}* allele, which expresses *GFP* from the *Gbx2* locus [43, 44]. We examined the distribution of *GFP*⁺ TCA in coronal and sagittal sections through the forebrain in control (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/+}*) and mutant (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/F}*) embryos. At E14.5~E16.5, in control embryos, *GFP*⁺ thalamic axons exiting the thalamus were found to extend rostrally through the prethalamus in smooth and parallel arrays of fascicles (Fig. 2A4, A5, A6, A13 and Fig. 2B1, B3, B5). In contrast, in *Isl1* mutant embryos, many thalamic axons fasciculated abnormally to form much denser, thicker and more disordered bundles in the prethalamus (Fig. 2A10, A11, A12, A13, red arrows, white asterisks; B2, B4, B6, white arrows). TCAs within the thalamus are obscured by the intense *GFP* fluorescence expressed by cell bodies. Therefore, the TCA projection was also examined by an antibody against medium chain neurofilament (NF-M) expressed on TCAs [45]. Strikingly, abnormally thick bundles were also detected even within the thalamus, and some of the *GFP*⁺ neurofilament⁺ (NF⁺) fibers were disoriented and failed to extend rostrally through the prethalamus but instead were misrouted caudally into the pretectum (Fig. 2A9, white arrows; B2, B4, B6, white arrowheads; C4', C4'' white arrowheads). Normally, thalamic axons exiting the prethalamus make a sharp turn to avoid the hypothalamus and enter the telencephalon (Fig. 2A1-A6). In contrast, in *Isl1*-deficient embryos, some thalamic axons failed to cross the boundary between the diencephalon and telencephalon

Fig. 2 Loss of *Isl1* leads to TCA pathfinding defects in the prethalamus and thalamus. **(A)** Immunohistochemistry for GFP on coronal sections of control (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/+}*) (A1-A6) and mutant (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/F}*) (A7-A12) embryos at E16.5. The red arrows in A10 and A11 indicate abnormal TCA projections in the prethalamus of *Isl1* mutant embryos. White asterisks in A10, A11, and A12 indicate abnormally large bundles of TCAs crossing the prethalamus and entering the ventral telencephalon in *Isl1* mutants compared to controls. *GFP*⁺ TCAs misrouted caudally to the habenula (white arrows in A9). Red asterisks in A10-A12 mark abnormal fasciculation of TCAs within the thalamus. *GFP*⁺ TCAs misrouted ventrally in the ventral telencephalon (A7-A11, red arrowheads) and hypothalamus (A12, yellow arrowhead). In the cortex, *Isl1* mutant TCAs were shorter than those of control embryos (A7-A11, white arrowheads). **(A13)** Examples of the measurements taken for the quantification. Yellow dashed lines in A4, A5, A10, A11 indicate the position of the lines used to quantify the number of *GFP*⁺ fluorescent signals crossing the prethalamus. (n = 5 embryos; Student's *t*-test; **p* < 0.001). **(B)** Double immunofluorescence for GFP and NF-M on sagittal sections of control and *Isl1* mutant embryos at E14.5. Control TCAs extended in parallel and oriented ventrolaterally, forming a thin fasciculus in the thalamus and prethalamus, including the TRN. In contrast, *Isl1* mutant TCAs formed an abnormally thick fasciculus and extended randomly in the thalamus (white arrowheads) and prethalamus (white arrows). **(C)** Double immunofluorescence for GFP and NF-M on sagittal sections of control and *Isl1* mutant embryos at E18.5. In the thalamus, *GFP*⁺ TCAs formed abnormally thick axon bundles orienting randomly and misrouting caudally into the pretectum (white arrowheads in C4', C4''). Cx, cerebral cortex; Eth, epithalamus; Hyp, hypothalamus; Prt, pretectum; Pt, prethalamus; Th, thalamus. Scale bars, 200 μm

and instead invaded the hypothalamic region ventrally (Fig. 2A12, yellow arrowheads). Moreover, many thalamic axons that entered the ventral telencephalon were misrouted ventrally at E16.5 (Fig. 2A7-A11, red arrowheads). We also observed *GFP*⁺ axons in the subplate layer of the cortex, but the majority of them stalled at the midpoint of the cortical areas (Fig. 2A7-A11, white arrowheads).

As *Isl1* expression is also lost in the ventral telencephalon, we next sought to determine the developmental origin of TCA defects in *Isl1*-deficient mutants. We therefore generated telencephalic-specific inactivation by crossing the *Isl1^{F/F}* allele with the *Foxg1-IRES-Cre* mouse line, in which an *IRES-Cre* was inserted in the 3' UTR of the *Foxg1* locus to prevent *Foxg1* haploinsufficiency and ectopic *Cre* expression found in the widely used *Foxg1-Cre* mice [46]. In *Foxg1-IRES-Cre; Isl1^{F/F}* embryos, *Isl1* expression was completely lost in the telencephalon but remained in other brain regions, including the prethalamus (Fig. S4E-H). We then crossed the *Foxg1-IRES-Cre; Isl1^{F/F}* allele with the *Gbx2^{GFP}* allele. In *Gbx2^{GFP}; Foxg1-IRES-Cre; Isl1^{F/F}* embryos, *GFP*⁺ NF⁺ thalamic axons emerging from the thalamus converged to form normal TCA bundles as they crossed the prethalamus in a pattern similar to those in controls (Fig. S5B, D, F, H). In the ventral telencephalon, some *GFP*⁺ NF⁺ axons were disorganized and ran ectopically toward the ventral floor (Fig. S5E-H, arrowheads). Thalamic axons that entered the cortex exhibited delayed



outgrowth compared to those of controls (Fig. S5B, C, D, F, G, H, arrows). Therefore, deletion of telencephalic *Is11* can cause TCA defects to a lesser extent than loss of *Is11* in both the diencephalon and telencephalon. Taken together, these results suggest that thalamo-cortical connectivity is dependent on the functions of *Is11* from the telencephalon

and diencephalon, but diencephalic *Is11* may play a more significant role in TCA projection.

Isl1 represses the expression of *Efna5*, which inhibits thalamic neurite outgrowth

To further understand how defective TRN differentiation resulting from *Isl1* loss leads to abnormal fasciculation and misrouting of TCAs in the prethalamus, we examined the distribution of axon guidance molecules in the developing prethalamus. Quantitative RT-PCR analysis in E13.5 prethalamus revealed that *Efna5*, a member of the Eph receptor-interacting ligand family was significantly upregulated in *Isl1*-deficient prethalamus (Fig. 3A). We then verified the differential expression of *Efna5* by RNA

in situ hybridization. In control embryos, *Efna5* was largely undetectable in the TRN (Fig. 3B1, B7), while we observed strong upregulation of *Efna5* in *Dlx5/6-Cre; Isl1^{F/F}* embryos (Fig. 3B4, B10). *Epha4* and *Epha7*, which encode the receptors for *Efna5*, appeared to be unchanged in the absence of *Isl1* (Fig. 3B2, B3, B5, B6, B8, B9, B11, B12). To examine whether ectopic upregulation of *Efna5* might affect TCA navigation into the prethalamus, thalamic explants were prepared from control (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/+}*) or mutant embryos (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/F}*) and cocultured with aggregates of *Efna5*-expressing cells. When cocultured with mock-transfected cells, thalamic explants derived from




Fig. 3 Loss of *Isl1* derepresses the expression of *Efna5*, a repellent for TCAs, in the TRN. **(A)** Differential expression of *Efna5* in the prethalamus of E13.5 mutant embryos (*Dlx5/6-Cre; Isl1^{F/F}*) compared with control embryos (*Dlx5/6-Cre; Isl1^{F/+}*) based on qRT-PCR. Prethalamic *Efna5* expression was significantly elevated in *Isl1* mutant embryos (two-way ANOVA with Sidak's multiple comparison test; *** $p \leq 0.001$). **(B)** RNA in situ hybridization for *Efna5*, *Epha4*, and *Epha7* on coronal sections of control and *Isl1* mutants at E13.5 and E14.5. Loss of *Isl1* resulted in significant upregulation of *Efna5* in the TRN (red dashed areas), despite similar staining in other brain regions. Scale bar, 200 μ m. (B13) Quantification of in situ hybridization. The pixel intensity values of TRN were grouped and averaged from

three different sections per embryo. ($n = 3$ embryos; Student's t -test; ** $p < 0.01$) **(C)** Thalamic explants from control (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/+}*) and mutant (*Gbx2^{GFP}; Dlx5/6-Cre; Isl1^{F/F}*) embryos were cocultured with *Efna5*-expressing cells (outlined by a white dashed line). Explants were photographed, and outgrowth from the distal and proximal sides of the explants was quantified by GFP fluorescence-occupied area. The values were averaged from two explants per embryo, and the averaged values from three independent experiments were plotted. A significant increase in the distal-proximal (D:P) fluorescence ratio was observed in the presence of *Efna5*-expressing cells (two-way ANOVA with Sidak's multiple comparison test; * $p < 0.05$). Pt, prethalamus; Th, thalamus; TRN, thalamic reticular nucleus

control or mutant embryos grew long neurites (Fig. 3C). In contrast, both control and mutant explants exhibited significantly shorter neurites when cocultured with *Efna5*-expressing cells (Fig. 3C). These results suggest that *Is11* is required to repress the expression of *Efna5*, which interferes with the normal growth of TCA passing through the prethalamus.

Prethalamo-thalamic axons (PTAs) precede TCAs, and loss of PTAs by *Is11* inactivation causes the pathfinding defects of TCAs in the thalamus

Our findings that abnormal fasciculation and misrouting of TCA were also evident within the thalamus itself led us to investigate whether *Is11* deletion affected patterning or regionalization of the thalamus, although the expression pattern of *Is11* does not suggest a role in thalamic development. We first analyzed the effects of *Is11* loss on early thalamic differentiation. *Hes5*, *Sox2*, *Elavl3/4*, and *Olig2* were similarly expressed in control and *Is11*-deficient thalamus (Fig. S2A–D, I). We next examined the expression profiles of a panel of transcription factors whose functions influence TCA development. Loss of *Neurog2* or *Lhx2* disrupts normal TCA growth and pathfinding [47, 48]. Previous genetic studies demonstrated crucial functions of *Gbx2* and *Tcf7l2* in regulating correct TCA guidance [44, 49]. During development, we did not observe significant alterations in the distribution of these factors in *Is11*-deficient thalamus (Fig. S6). We also examined the distribution of additional postmitotic neuronal markers or axon guidance molecules, and none of these markers expression were altered in the thalamus of *Dlx5/6-Cre; Is11^{F/F}* embryos (Fig. S6). Overall, our gene expression analysis indicated that *Is11* deletion does not significantly perturb the molecular regionalization of the thalamus. Therefore, TCA abnormalities are unlikely to result from obvious defects in thalamic development.

Neurons within the prethalamus extend axons to the thalamus. These prethalamo-thalamic axons (PTAs) have been suggested to act as pioneer axons for TCA navigation [50–52]. However, the developmental and spatiotemporal relationships between these two axonal projections remain largely unknown. We thus investigated whether PTAs are involved in correct TCA formation within the thalamus. To mark PTAs, we crossed the *Dlx5/6-Cre* allele with the *R26-tdTomato* mouse line. At E13.5 and E16.5, we observed tdTomato⁺ axons that emerged from the prethalamus and extended into the thalamus of *Dlx5/6-Cre; R26-tdTomato* embryos (Fig. 4A). To address the temporal relationships between PTAs and TCAs, we simultaneously labeled these two axonal pathways by crossing the *Gbx2^{GFP}* reporter line onto the *Dlx5/6-Cre; R26-tdTomato* mouse line. At E11.5, a significant portion of tdTomato⁺ PTAs emerged from the marginal zone of the developing prethalamus and extended

caudally through the thalamus (Fig. 4B1, arrowheads), while we did not observe TCAs entering the prethalamus, indicating that PTAs precede TCAs. To assess the spatial relationships between these axonal projections within the thalamus, we visualized TCAs with NF-M immunofluorescence because after E11.5, GFP⁺ TCA fibers are masked by the bright GFP staining expressed by cell bodies. We found that tdTomato⁺ prethalamic fibers and NF-M⁺ thalamic fibers exhibited close associations in the thalamus (Fig. 4C3, C9). To address whether *Is11* is required for the formation of PTAs, we crossed mice carrying the floxed *Is11* allele and *R26-tdTomato* with the *Dlx5/6-Cre* line. *Is11* deletion in the prethalamus caused a profound reduction in the number of tdTomato⁺ axons projecting from the prethalamus to the thalamus in E13.5 and E14.5 embryos (Fig. 4C4, C10, C13). In the thalamus of control embryos, we observed tdTomato⁺ axons and NF-M⁺ TCAs in ordered and parallel arrays (Fig. 4C2, C3, C8, C9), while NF-M⁺ TCAs exhibited erroneous and disorganized trajectories in the thalamus of *Is11*-deficient embryos (Fig. 4C5, C6, C11, C12), suggesting a potential pioneering role of PTAs in guiding thalamic axons.

Is11 is also expressed in the ventral telencephalon, and neurons in the ventral telencephalon project to the thalamus [53]. To confirm whether the tdTomato⁺ axons that were lost in *Dlx5/6-Cre; Is11^{F/F}; R26-tdTomato* embryos originated from the prethalamus, we injected the neuronal tracer Neurovue into the prethalamus of E13.5 control and *Dlx5/6-Cre; Is11^{F/F}* embryos. Neurovue placed in the prethalamus of control embryos successfully labeled axons projecting to the thalamus, while we did not observe Neurovue⁺ axons passing through the thalamus in the absence of *Is11* (Fig. 4D). Taken together, these results suggest that *Is11* regulates correct TCA projections within the thalamus by promoting proper formation of PTAs.

Prolonged *Is11* function is required to maintain TRN neuron fate

Given that *Is11* expression persists in the TRN during late embryogenesis (Fig. S1C), our observations raise the intriguing possibility that *Is11* has a continued role in prethalamic development. To address whether the dependency of TRN development on *Is11* is temporally regulated, we took advantage of a newly generated mouse line that drives Cre-mediated recombination in the forebrain. This driver relies on a Sox2-bound regulatory element (*SBR*), which was previously shown to direct the transcription of a reporter gene to the telencephalon and diencephalon at late developmental stages [54]. To determine the efficiency of Cre-mediated recombination, *SBR-Cre* transgenic mice were generated and crossed with a *R26-tdTomato* reporter strain. At E16.5,

Figure 4




Fig. 4 *Isll* is required for the formation of prethalamo-thalamic pioneer axons. **(A)** Immunohistochemistry for tdTomato on coronal sections of *Dlx5/6-Cre; R26-tdTomato* embryos at E13.5 and E16.5. Prethalamo-thalamic axons (PTAs) labeled by tdTomato extended into the thalamus, forming ordered and parallel projections. **(B)** Costaining for tdTomato and GFP on coronal sections of *Dlx5/6-Cre; R26-TdTomato; Gbx2^{GFP}* embryos at E11.5. PTAs labeled with tdTomato extended into the thalamus, while GFP⁺ thalamic axons had yet to enter the prethalamus. **(C)** Costaining for tdTomato and NF-M on coronal sections of control (*Dlx5/6-Cre; Isll^{F/+}; R26-tdTomato*) and mutant (*Dlx5/6-Cre; Isll^{F/F}; R26-tdTomato*) embryos at E13.5 and E14.5. Loss of *Isll* caused a visible reduction in the number of tdTomato⁺ axons projecting from the prethalamus to the thalamus in E13.5 and E14.5 mutant embryos. Control NF-M⁺ thalamic axons formed ordered and parallel projections, but mutant NF-M⁺ thalamic axons aggregated into thick bundles that ran laterally. **(C13)** Examples of the measurements taken for the quantification. Yellow dashed lines in C1, C4, C7, C10 indicate the position of the lines used to quantify the number of axon bundles crossing the thalamus. (two-way ANOVA with Sidak's multiple comparison test; **p* < 0.05, ***p* < 0.01, ****p* < 0.001). **(D)** Implanting the chemical tracer Neurovue into the prethalamus of control (*Dlx5/6-Cre; Isll^{F/+}*) at E13.5 visualized PTA projections across the thalamus. Coronal sections from five independent experiments revealed a defective pattern in the outgrowth of PTAs in mutant embryos (*Dlx5/6-Cre; Isll^{F/F}*) similar to that shown by tdTomato immunohistochemistry in *Dlx5/6-Cre; Isll^{F/F}; R26-TdTomato* embryos. Pt, prethalamus; Th, thalamus. Scale bars: 200 μm

strong tdTomato staining was detected in the developing forebrain (Fig. S7A, B, C). This *SBR-Cre* allele was then crossed with *Isll^{F/F}* mice to generate conditional mutant progeny. *Isll* staining was almost completely lost in the prethalamus of *SBR-Cre; Isll^{F/F}* embryos at E16.5 (Fig. S7J-O). Like in the prethalamus of *Dlx5/6-Cre; Isll^{F/F}* mutants, *Dlx1* and *Meis2* expression was significantly downregulated in the TRN of *SBR-Cre; Isll^{F/F}* embryos (Fig. 5G, H, M). Moreover, we observed ectopic activation of *Arx*, *Pax6*, and *Lhx1/5* in the TRN of *SBR-Cre; Isll^{F/F}* mutants in a pattern similar to that of *Dlx5/6-Cre; Isll^{F/F}* mutants (Fig. 5I-L, M), indicating that *Isll* continues to control TRN identity during embryogenesis.

***Ascl1* is required for promoting TRN neuron fate and PTA outgrowth and regulates *Isll* expression in the prethalamus**

The TCA pathfinding defects resulting from the loss of *Ascl1* [37] closely resemble the defects in TCAs caused by *Isll* deficiency. *Ascl1* mutant embryos exhibit abnormal growth and pathfinding of TCAs in the developing forebrain [37]. To explore whether these errors are due to the disruption of prethalamo factors, we analyzed the *Ascl1^{KI}* allele, in which the entire coding region of *Ascl1* was replaced with *GFP* [55]. Similar to the phenotype described for *Isll*-deficient mutants, the loss of *Ascl1* caused severe downregulation of *Dlx1* in the TRN of the prethalamus (Fig. 6A6, A16). In contrast to the *Isll*-deficient mutants, *Dlx1* expression was also lost in the vLG and *zli* in the absence of *Ascl1*

(Fig. 6A6, A16). *Meis2* expression was greatly reduced in the TRN of *Ascl1* mutants in a pattern similar to that of *Isll*-deficient mutants (Fig. 6A7, A17). The narrow band corresponding to *Arx*, *Pax6*, or *Lhx1* expression along the *zli* was mostly missing, and the expression of these genes was also lost in the vLG in the absence of *Ascl1* (Fig. 6A8, A9, A10, A18, A19, A20). In contrast, *Arx*, *Pax6*, and *Lhx1* expression was ectopically induced in the TRN of *Ascl1^{KI/KI}* mutants (Fig. 6A8, A9, A10, A18, A19, A20). These data suggest that, similar to *Isll*, *Ascl1* is required to promote TRN identity and repress non-TRN prethalamo cell fates within the TRN and that unlike *Isll*, *Ascl1* is also important for the differentiation of other prethalamo nuclei.

We next analyzed circuit formation between the prethalamus and thalamus. Consistent with previous observations [37], NF-M⁺ thalamic axons formed abnormally thick fascicles and extended randomly in the prethalamus (Fig. 6B3, B4). Axonal arrangement was also severely disrupted within the thalamus of *Ascl1^{KI/KI}* mutants. NF-M⁺ thalamic axons formed thin fascicles and were arranged in parallel in the control thalamus, whereas those in *Ascl1* mutants formed thick bundles and crossed each other with abnormal overlapping course of axons (Fig. 6B3, B4, arrows). Although defective TCAs within the thalamus could be a secondary consequence of a total failure in morphological maturation of the prethalamus, we assessed the potential importance of PTAs in the establishment of thalamocortical connectivity. We therefore crossed mice carrying the *Ascl1* null allele and *R26-tdTomato* with the *Dlx5/6-Cre* line. Loss of *Ascl1* resulted in a marked reduction in the number of tdTomato⁺ axons projecting from the prethalamus to the thalamus in E13.5 and E14.5 embryos (Fig. 6C). When the Neurovue tracer was injected into prethalamo regions, Neurovue labeling accumulated in the prethalamus of both control and mutant embryos, but Neurovue⁺ axons were not apparent in the thalamus of *Ascl1* mutants (Fig. 6D), confirming that *Ascl1* deletion disrupts the formation of axons that project from the prethalamus to the thalamus. These results demonstrate that *Ascl1* and *Isll* have a significant degree of overlapping regulatory function in prethalamo differentiation and circuit formation.

We then investigated the gene regulatory hierarchy between *Isll* and *Ascl1*. In the developing prethalamus, *Ascl1* expression is restricted to ventricular zone progenitors (Fig. S2E), whereas *Isll* is expressed both in the progenitor and postmitotic regions (Fig. 6E1, E2). When in situ hybridization for *Isll* on coronal sections was performed with *Shh*, a *zli*-specific marker, to locate the affected area more precisely, we found that *Isll* expression was lost in the prethalamus of *Ascl1^{KI/KI}* mutant embryos (Fig. 6E3, E4). In contrast, *Ascl1* expression was largely unaffected in the prethalamus of *Dlx5/6-Cre; Isll^{F/F}* mutants (Fig. S2E).

Figure 5




Fig. 5 *Isl1* continues to regulate TRN identity during late embryogenesis (A–L) In situ hybridization for prethalamic markers on control (*SBR-Cre; Isl1^{F/+}*) and mutant (*SBR-Cre; Isl1^{F/F}*) coronal sections at E16.5. *Dlx1* expression in the TRN but not in other prethalamic nuclei was lost in *Isl1* mutant embryos (G). *Meis2* expression, which was restricted to the TRN of control embryos, was abrogated in mutant

embryos (H). Loss of *Isl1* resulted in ectopic induction of *Arx*, *Pax6*, and *Lhx1/5* in the TRN (I–L). (M) Quantification of in situ hybridization. The pixel intensity values of TRN or vLG were grouped and averaged from three different sections per embryo ($n=3$ embryos; Student's *t*-test; * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$). Scale bars, 200 μm

These observations revealed a crucial role for *Ascl1* in the regulation of *Isl1* expression in the prethalamus.

***Isl1* is necessary for *Ascl1*-mediated fate specification and neurite outgrowth in in vitro cultured prethalamic neurons**

The above-described observations led us to ask whether *Isl1* is an essential component of *Ascl1*-mediated genetic programs that support neuronal fate specification and connectivity of the TRN. To address this question, we established primary cell cultures from the prethalamus of E13.5 *Ascl1^{KI/+}* and *Ascl1^{KI/KI}* embryonic brains. To verify whether cultured cells were indeed derived from TRN tissues, cells that had been cultured for 2 days in vitro (DIV) were immunostained with *Isl1*, *Dlx1*, and *Pax6* antibodies. The majority of primary cultured cells from control TRN tissues were *Isl1⁺*, *Dlx1⁺* and *Pax6⁻*, while *Ascl1*-deficient cells exhibited

Isl1⁻, *Dlx1⁻* and *Pax6⁺* immunoreactivity (Fig. 7A, B), indicating TRN cell identity. We next examined neurite outgrowth of neurons in primary cultures from *Ascl1^{KI/+}* and *Ascl1^{KI/KI}* embryos using Tuj1, a neuron-specific class III beta-tubulin that is widely used to visualize neuronal extensions. We measured the number of neurites, the length of the longest neurite, and the total length of neurites to assess neurite outgrowth in primary cultures. Consistent with our embryo experiments, *Ascl1^{KI/KI}* primary cultured neurons developed fewer neurites than did *Ascl1^{KI/+}* neurons at DIV2 and DIV6 (Fig. 7C, D). The longest neurites and the total length of neurites in *Ascl1^{KI/KI}* neurons were shorter than those in *Ascl1^{KI/+}* neurons (Fig. 7C, D). To assess the ability of *Isl1* to rescue the TRN phenotypes caused by *Ascl1* deficiency, an *Isl1* expression construct was transfected into *Ascl1^{KI/KI}* TRN cells that had been cultured for 1 DIV together with a *tdTomato* reporter expression vector to identify the transfected cells. After 6 additional days of culture,

the tdTomato⁺ cells were evaluated for neuron identity and neurogenesis. Compared with that in mock-transfected *Ascl1*^{KI/KI} cells, the number of Dlx1⁺ cells in primary cultures of *Ascl1*^{KI/KI} cells transfected with the *Isll* expression construct increased, while the number of Pax6⁺ cells in *Isll*-transfected cells decreased (Fig. 7E, F). For each Tuj1⁺ cell, the number of neurites was greater in *Ascl1*-deficient cells transfected with the *Isll* expression construct than in mock-transfected cells (Fig. 7G, H). The longest neurites and the total length of neurites in *Isll*-transfected *Ascl1*^{KI/KI} cells were longer than those in mock-transfected cells (Fig. 7G, H), indicating that *Isll* significantly rescued defective neurogenesis caused by *Ascl1* deficiency. Taken together, these results suggest that *Isll* is an important mediator of *Ascl1* function in the fate specification and axon formation of in vitro-derived TRN neurons.


Discussion

Our study demonstrated the key roles of the *Ascl1-Isll* regulatory cascade in orchestrating TRN neuronal fate specification and connectivity. A set of TRN-enriched genes, such as *Dlx1* and *Meis2*, was specifically downregulated in *Isll*-deficient TRN, while the loss of *Isll* did not influence *Dlx1* expression in other prethalamic nuclei. The importance of *Isll* in the determination of TRN neuronal identity was further evidenced by the concomitant induction of a set of TRN-depleted genes, such as *Arx*, *Pax6*, and *Lhx1/5*, in *Isll*-deficient TRN. This coordinated regulation by *Isll* implicates a central role in determining the cell fate of the TRN. Given that the *Gad1* expression pattern was unaltered in the entire prethalamus in the absence of *Isll*, the downregulation of TRN-enriched genes and upregulation of TRN-depleted genes were not due to deprivation of TRN tissue. Therefore, these findings indicate that the role of *Isll* in the developing prethalamus is likely to specify the fate of TRN cells by promoting TRN-enriched genes and suppressing TRN-depleted genes. Conditional deletion of *Isll* at the late developmental stage caused similar phenotypes, indicating that TRN cells continue to depend on *Isll* for their normal differentiation during late gestation. Embryonic inactivation of *Isll* causes abnormalities in the formation of TRN at adult stages, as demonstrated by reduced *Meis2* expression [28]. Previous studies demonstrated critical roles for *Isll* in specifying striatal neurons in the ventral telencephalon [28, 29]. Loss of *Isll* led to the downregulation of striatonigral genes and concomitant upregulation of striatopallidal genes, while forced expression of *Isll* repressed the striatopallidal genetic program, indicating that *Isll* plays dual roles by promoting striatonigral neuron identity and repressing striatopallidal neuron identity. With respect to the molecular

processes by which *Isll* regulates cell types, it has been reported that *Isll* controls motor neuron fate specification by cooperating with *Lhx3* and striatal neuron identity by interacting with *Lhx8* [56, 57]. Whether the differentiation of TRN neurons is dependent on the combined activity of *Isll* and other LIM homeodomain proteins requires further investigation.

In our study, the loss of *Isll* resulted in abnormal fasciculation and pathfinding of TCAs by disrupting the development of structures located on the path of thalamic axons. The TRN is thought to be a crucial terrain for axon projections because all cortico-thalamic and thalamo-cortical axons must cross the TRN. How does proper formation of the TRN regulated by *Isll* control the normal extension of TCAs? It is possible that in the absence of *Isll*, TCAs entering the prethalamus undergo an abrupt change in the expression levels of TRN-enriched/-depleted genes and encounter an abnormal attractive/repulsive environment. Previously, similar defects in the pathfinding of TCAs were observed in *Dlx1/2*^{-/-} mutant embryos [58]. Our results showed that disruption of TRN development by *Isll* inactivation was accompanied by dysregulated expression of the axon guidance molecule *Efna5*, inhibiting the growth of TCAs passing through the prethalamus. *Efna5*, which encodes one of the membrane-tethered ligands for EphA receptors, was not expressed at detectable levels in the wild-type TRN, while loss of *Isll* led to strong upregulation of this gene in the TRN. *Efna* ligands transduce the signaling of EphA receptors, leading primarily to cell repulsion [59]. Previous studies have demonstrated that *Efna5* functions as an inhibitor of thalamic axonal growth [60] or serves as a repellent cue of thalamic axons [61]. Our observations and those of others indicate that normal thalamo-cortical connectivity requires the correct expression pattern of *Efna5*, while the failure to regulate *Efna5* leads to misprojection of TCAs. It is therefore likely that another crucial role of *Isll* is to ensure the correct extension of TCAs by promoting appropriate regionalization of the prethalamus and preventing inappropriate expression of the axon guidance molecule.

The current study provides intriguing new perspectives on the growth and significance of PTAs extending into the thalamus. Another important new finding is that the loss of *Isll* resulted in abnormal fasciculation and random orientation of thalamic axons within the thalamus despite that *Isll* deletion had no impact on the formation of the thalamus. Disrupted neuronal specification in the TRN and ectopic expression of the repellent *Efna5* in the prethalamus do not account for all TCA defects within the thalamus because many disordered thick bundles were also detected in the caudal thalamus distant from the prethalamus, and some of the misrouted fibers extended more caudally into the pretectum. It is, therefore, likely that in the absence



of *Isl1*, TCAs might have undergone abnormal fasciculation and pathfinding errors to a certain degree before leaving the thalamus. These results suggest that there must be

additional factors underlying the phenotypes. It has been suggested that prethalamic nuclei, including the TRN, contain a population of cells that extend axons to the thalamus

Fig. 6 *Ascl1* controls TRN cell fate and PTA outgrowth and is essential for *Isll* expression in the prethalamus. **(A)** In situ hybridization for prethalamic markers on control (*Ascl1*^{KI/+}) and mutant (*Ascl1*^{KI/KI}) coronal sections at E14.5 and E16.5. In *Ascl1* mutants, *Dlx1* expression was lost in the TRN as well as in the rZI, vLG, and zli (A6, A16). Loss of *Ascl1* resulted in severe downregulation of *Meis2* expression in the TRN (A7, A17). *Arx*, *Pax6*, or *Lhx1* expression in the vLG and zli of *Ascl1*^{KI/KI} mutants was downregulated but ectopically induced in the TRN (A8–A10, A18–A20). **(A21)** Quantification of in situ hybridization. The pixel intensity values of TRN or vLG were grouped and averaged from three different sections per embryo ($n=5$ embryos; Student's *t*-test; ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). **(B)** Immunohistochemistry for NF-M on coronal sections of control (*Ascl1*^{KI/+}) and mutant (*Ascl1*^{KI/KI}) embryos at E14.5 and E16.5. In control embryos, NF-M⁺ thalamic axons extended in ordered and parallel arrays that were less fasciculated in the thalamus and prethalamus (B1, B2) than in mutant embryos (B3, B4). Moreover, in *Ascl1* mutants, thick NF-M⁺ bundles crossed each other with abnormal overlapping course of axons (arrows in B3, B4). **(C)** Immunohistochemistry for tdTomato on coronal sections of control (*Dlx5/6-Cre*; *R26-TdTomato*; *Ascl1*^{KI/+}) and mutant (*Dlx5/6-Cre*; *R26-TdTomato*; *Ascl1*^{KI/KI}) embryos at E13.5 and E14.5. The control prethalamus formed ordered and parallel tdTomato⁺ projections to the thalamus (C1, C3), while very few PTAs were detected in the mutant embryos (C2, C4). **(C5)** Examples of the measurements taken for the quantification. Yellow dashed lines in C1–C4 indicate the position of the lines used to quantify the number of axon bundles crossing the thalamus. ($n=3$ embryos; two-way ANOVA with Sidak's multiple comparison test; ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). **(D)** Implanting the chemical tracer Neurovue into the prethalamus of control (*Ascl1*^{KI/+}) and mutant embryos (*Ascl1*^{KI/KI}) at E13.5. Compared to those in controls (D1), no Neurovue⁺ PTAs were labeled in the thalamus in the absence of *Ascl1* (D2). **(E)** In situ hybridization for *Isll* and *Shh* on control (*Ascl1*^{KI/+}) and mutant (*Ascl1*^{KI/KI}) coronal sections at E12.5. *Shh* is a specific marker for the zli. Loss of *Ascl1* abrogated *Isll* expression in the TRN. **(E5)** Quantification of in situ hybridization. The pixel intensity values of TRN were grouped and averaged from four different sections per embryo ($n=4$ embryos; Student's *t*-test; **** $p < 0.0001$). Pt, prethalamus; Hyp, hypothalamus; Pt, prethalamus; rZI, rostral zona incerta; Th, thalamus; TRN, thalamic reticular nucleus; vLG, ventral lateral geniculate; zli, zona limitans intrathalamica. Scale bars, 200 μ m

and function to guide TCA navigation [37, 50–52]. First, we found that proper formation of PTAs relies on *Isll* function. Second, we determined the relative developmental timing between TCAs and PTAs because if PTAs pioneer TCAs, PTA outgrowth should precede the extension of TCAs into the prethalamus. By simultaneous visualization of thalamic and prethalamic axons, we showed that PTAs begin to penetrate thalamic areas before TCAs invade the prethalamus. Third, *Isll* mutant mice phenocopy the TCA pathfinding defects observed in the prethalamus and thalamus of *Ascl1* mutant embryos [37]. We found that PTAs require *Ascl1* for their normal development and that *Isll* functions downstream of *Ascl1*. Therefore, our data and those of others corroborate a role for PTAs in guiding thalamo-cortical axons. However, further work will be required to dissociate the impact of PTAs on the pathfinding of TCAs from that of axon guidance molecules.

Our study uncovered striking similarities in the aberrant phenotypes of TRN neuron specification between *Isll* and *Ascl1* mutants. Furthermore, the phenotypes of defective prethalamo-thalamic and thalamo-cortical projections in *Isll* mutant brains were similar to those observed in *Ascl1* mutant embryos. However, there are some differences in the phenotypes between *Ascl1* mutant mice and *Isll* mutant mice. Loss of *Ascl1* disrupted neuronal differentiation in all of the prethalamic nuclei, while *Isll* inactivation affected the development of the TRN but not the remainder of the prethalamus. This finding suggested that TRN neurons are very different from other prethalamic neurons. As *Ascl1* is expressed in the progenitor region along the anteroposterior axis of the prethalamus and has the ability to specify neuronal progenitors, it is likely that loss of *Ascl1* could block the generation of committed neuronal precursors in the prethalamus. Previously, in *Ascl1* mutant mice, multiple neurogenesis defects, including defects in the proliferation and neuronal specification of progenitor cells, have been observed in the telencephalon, and midbrain [36, 62, 63]. Notably, we found that *Isll* is functionally required for *Ascl1*-mediated neuronal specification and axonal projections in in vitro cultured TRN cells. These findings suggest that *Ascl1* may regulate the distribution of *Isll*, which may, in turn, affect TRN differentiation. However, the impairments in gene expression and neurite outgrowth in in vitro cultured *Ascl1*-deficient cells could be partially restored by forced expression of *Isll*, suggesting that the ability of *Ascl1* to promote TRN differentiation is unlikely to be mediated entirely by *Isll*. The question of whether parallel action by other transcription factors participates in the regulation of TRN development by *Ascl1* needs further investigation.

Materials and methods

Mouse lines

The generation of *Isll*^{loxP}, *Ascl1*^{KI}, *Dlx5/6-Cre*, *Foxg1-IRES-Cre*, and *R26-tdTomato* mice obtained from The Jackson Laboratory was described previously [38, 39, 46, 64]. All animals used for these experiments were maintained on mixed backgrounds. To confirm mating, vaginal plugs were checked each morning, and plug dates were considered as E0.5.

Production of transgenic mice

The *SBR* sequence was amplified by PCR with the primers 5'-ATTAGCGGCCGCCCTTTCTTTCTGTCTGCTGATTGCC-3' and 5'-ATTAGCGGCCGCATGTTCAAC TCCTTGGAACCTACC-3' and cloned into the *NotI* site

7




Fig. 7 *Ascl1* requires *Is11* to promote TRN neuronal specification and neurite outgrowth in cultured neurons. **(A, B)** Isolation and primary culture of TRN cells from E13.5 control (*Ascl1^{K1/+}*) and *Ascl1^{K1/K1}* mutant embryonic brains. TRN cells were cultured on coverslips coated with L-ornithine and laminin in 24-well plates. TRN cell identity was verified by immunocytochemistry of DIV2 cells using antibodies against *Isl1*, *Dlx1* and *Pax6*. Consistent with the gene expression profiles of the embryos, most of the control cultured cells derived from *Ascl1^{K1/+}* TRN were *Isl1⁺*, *Dlx1⁺*, and *Pax6⁻*, while many of the *Ascl1^{K1/K1}* cells were *Isl1⁻*, *Dlx1⁻*, and *Pax6⁺*. A total of 100 DAPI⁺ cells were quantified for each field, and three measurements were averaged for each coverslip. The average values from six coverslips prepared from three embryos were plotted for each genotype (Student's *t*-test; ***p* ≤ 0.01). **(C, D)** Tuj1 immunostaining was performed at DIV2 and DIV6 to determine the number of neurites, the length of the longest neurite, and the total length of neurites. Quantification of the number of neurites, length of the longest neurite, and total length of neurites were achieved from 20 neurons for each field, and three measurements were averaged for each coverslip. The average values from ten coverslips prepared from five embryos were plotted for each genotype (two-way ANOVA with Sidak's multiple comparison test; ***p* < 0.01, *****p* < 0.0001). **(E-H)** TRN cells isolated from *Ascl1^{K1/K1}* mutant E13.5 brains were cultured for 1 DIV and transfected with an *Is11* expression construct (*pCMV-Is11*) or an empty vector (*pCMV*). The reporter expression vector (*pCMV-tdTomato*) was cotransfected to identify the transfected cells. **(E, F)** Quantification was achieved from transfected *Ascl1^{K1/K1}* mutant cells cultured for 5 additional DIV by counting *Dlx1⁺* or *Pax6⁺* cells among 100 tdTomato⁺ cells for each field. Three measurements were averaged for each coverslip, and the average values from eight coverslips prepared from four embryos were plotted for each genotype (Student's *t*-test; ***p* < 0.01). **(G, H)** The number of neurites, length of the longest neurite, and total length of neurites were measured for each tdTomato⁺ neuron cultured for 5 additional DIV following transfection. Quantification was achieved from 20 tdTomato⁺-transfected cells for each field. Three measurements were averaged for each coverslip, and the average values from ten coverslips prepared from five embryos were plotted for each genotype (Student's *t*-test; **p* < 0.05, ***p* ≤ 0.01)

of an expression construct containing a *β-globin* minimal promoter, the *Cre* gene, and an *SV40 poly(A)* signal. The resulting plasmid transgene was linearized with *Sall* for microinjection as previously described [54]. Stable transgenic mouse lines were generated by pronuclear injection into fertilized eggs derived from the *FVBN* mouse strain.

Section in situ hybridization

The pairs of PCR primer sequences used to generate template DNA for in vitro transcription by T7 RNA polymerase were obtained from the Allen Brain Atlas or designed against unique regions of transcripts to avoid cross-reactivity (Supplementary Table 1). Embryonic brains were collected from timed pregnant females. Section in situ hybridization were performed as described previously [49]. The brains were fixed overnight in 4% paraformaldehyde at 4 °C, washed three times in PBS, pH7.4, submerged in 30% sucrose in PBS, pH7.4, at 4 °C, embedded in optimal cutting temperature embedding medium (OCT), quickly frozen on dry ice and cryosectioned at 25 μm. Experiments for any given

riboprobe were performed in at least three independent biological replicates.

To quantify the signal intensity of in situ hybridization, after the stained sections were photographed under the same illumination conditions, all images were converted to 8-bit grayscale using Fiji software [65]. The mean pixel intensity of the staining signal was obtained by subtracting the mean intensity value of the background region from that of the stained region.

Immunostaining

For immunohistochemistry, brains were fixed in 4% paraformaldehyde in PBS, pH7.4, for 2 h at 4 °C, immersed in 30% sucrose, embedded in OCT compound, and sectioned using a cryostat at 25 μm. The cryosections were washed with PBS, pH7.4, containing 0.4% Triton X-100 and incubated in blocking buffer containing 0.4% Triton X-100, 10% sheep serum and 5% Mouse on Mouse (MOM) blocking reagent (VectorLabs, MKB-2213-1) in PBS, pH7.4, for 2 h at 4 °C. For immunocytochemistry, coverslips containing prethalamic neurons obtained from cell culture were washed with PBS, pH7.4, containing 0.1% Triton X-100 and incubated in blocking buffer containing 0.4% Triton X-100, 10% sheep serum and 5% MOM blocking reagent in PBS, pH7.4, for 1 h at 4 °C. Sections or coverslips were then incubated overnight at 4 °C with the following primary antibodies: anti-Tubulin beta III isoform (Millipore, MAB1637, 1:600), anti-NF-M (DSHB, 2H3, 1:100), anti-GFP (Abcam ab6673, 1:500), anti-*Isl1* (DSHB, 39.3F7, 1:100), anti-tdTomato (SIGGEN, AB8181–200, 1:500), anti-*Dlx1* (Chemicon, AB5724, 1:400) and anti-*Pax6* (DSHB, 1:100). Following incubation with primary antibodies, sections or coverslips were incubated with species-specific secondary antibodies conjugated to Alexa Fluor (Molecular Probes, A11034, A11003, A11010, A11029, A11055, A11056; 1:200).

For quantification of number of TCAs, we positioned a line across the prethalamus, and generated a GFP intensity profile using Fiji software. Intensity profiles were then processed by tracing and quantifying the number of GFP⁺ fluorescent signals crossing the line. For quantification of number of PTAs, we positioned three lines across the thalamus (1: at the thalamic-prethalamic border; 2: at a caudal thalamic region; 3: at the midpoint position between the two other lines), and generated a tdTomato intensity profile.

Quantitative reverse transcription PCR

Brains were dissected from *Dlx5/6-Cre; Is11^{F/+};R26-tdTomato* or *Dlx5/6-Cre; Is11^{F/F};R26-tdTomato* embryos at E13.5 and then cut in half along the dorsal and ventral midline. Fluorescence by tdTomato expression allowed us

to distinguish prethalamal tissues from surrounding tissues. After prethalamal tissues from the two halves of the same embryo were harvested in TRIzol Reagent (Invitrogen), total RNA was isolated using an RNeasy Mini kit (Qiagen) and used to prepare cDNA using a SuperScriptIII first-strand synthesis system (Invitrogen). Quantitative PCR was carried out in duplicate for each RNA sample using QuantiTect SYBR Green Supermix (Qiagen) following the manufacturers' instructions. The reactions were monitored using an Mx4000 multiplex quantitative PCR system (Stratagene, La Jolla, CA). The housekeeping gene β -actin was used for normalization, and relative quantification was calculated using comparative threshold cycle values for three biological replicates. All primers used are listed in Supplementary Table 1.

Explant culture

Dissection and explant culture were carried out as described previously [44, 66]. Thalamic explants were isolated from E13.5 *Dlx5/6-Cre; Gbx2^{GFP}; Isl1^{F/+}* or *Dlx5/6-Cre; Gbx2^{GFP}; Isl1^{F/F}* embryos. Hanging drops of 293T cells transfected with *pCMV* alone or *pCMV-Efna5* were embedded in basement membrane matrices (Corning Matrigel). Thalamic explants were positioned approximately 200–400 μ m from the transfected 293T cell aggregates and cocultured in Neurobasal medium (ThermoFisher) containing B-27 supplements (Invitrogen) and 1% penicillin/streptomycin. After 48 h, the cultures were fixed in 4% paraformaldehyde in PBS, pH7.4, for 30 min at 4 °C. Assays for axon outgrowth were quantified by measuring the area of fluorescence associated with GFP⁺-axons extending from the distal or proximal sides of the explant with respect to the cell aggregate as described previously [66].

Primary neuron cultures and transfection

Embryonic brains were dissected from the *Ascl1^{KI}* mouse line at E13.5 in 3 cm sterile Petri dish containing ice cold dissection medium, consisting of Hanks' balanced salt solution (HBSS) (Gibco), 20 mM D-glucose (Sigma), 200 μ M ascorbic acid (Sigma), and 100 units/ml penicillin/streptomycin (Gibco) and then cut in half along the dorsal and ventral midline. GFP fluorescence, which labels *Ascl1*-expressing cells, allowed us to locate and dissect TRN tissues. TRN tissues were collected in a 1.5 ml sterile tube, and digested with StemPro Accutase Cell Dissociation reagent (Thermo Fisher Scientific) for 10–20 min at 37 °C. The digestion was stopped by removing the supernatant and washing the tissue with dissociation medium consisting of Neurobasal medium (Invitrogen), 2% B-27 supplement (Thermo Fisher Scientific), 2% B-27 supplement Plus (Thermo Fisher

Scientific), 1% FBS (Gibco), 200 μ M L-glutamine (Thermo Fisher Scientific) and 200 μ M ascorbic acid. The tissue was resuspended in 1 ml of dissociation medium and triturated to obtain single cell suspension. After the cells were spun at 200 \times g, the cell pellet was resuspended in the dissociation medium. The number of dissociated cells and the ratio of viable to damaged cells were determined by Trypan blue staining using a hemocytometer. The cell suspension was transferred on top of 12 mm coverslips coated with 20 μ g/ml poly-L-ornithine (Sigma) and 10 μ g/ml laminin (Thermo Fisher Scientific) (100,000 cells per coverslip). After 1 h of incubation in a humidified tissue culture incubator at 37 °C with 5% CO₂, the coverslips were carefully transferred into 24-well plates containing the dissociation medium. Transient transfection was performed at DIV1. The transfected plasmids (0.3 μ g) consisted of a mixture of 0.1 μ g of *pCMV-tdTomato* (a gift from Davidson M, Shaner N, and Tsien R; Addgene plasmid #54642) [67] + 0.2 μ g of *pCMV-Isl1* (Sino Biological plasmid #MG56983-UT). Mock transfection (0.3 μ g) consisted of 0.1 μ g of *pCMV-tdTomato* + 0.2 μ g of *pCMV* empty vector. For individual wells in 24-well plates, a total of 0.3 μ g of DNA was diluted in 25 μ l of Opti-MEM reduced serum medium (Gibco), and 2.5 μ l of Lipofectamine 2000 (Invitrogen) was diluted in 25 μ l of Opti-MEM in a separate tube. The diluted DNA-Lipofectamine mixture was incubated at RT for 20 min and applied to *Ascl1^{KI/KI}* cells.

Measurement of neurite outgrowth

For quantitation of neurite outgrowth, images of stained cultures were captured using a Leica DMI6000B digital camera (Leica Microsystems), and the number of neurites, the length of the longest neurite and the total length of neurites were scored from the images captured by using the neurite tracer plugin in ImageJ [68]. Images are optimized to reduce artifacts, subtract background staining, and enhance contrast. Following optimization, images were thresholded and skeletonized, and then neurite length was measured by tracing down Tuj1 staining from the edge of the cell body to the furthest point. Such measurements were carried out for every neurite of each neuron.

Statistical analysis

All the mutant phenotypes we observed in the *Dlx5/6-Cre; Isl1^{F/F}*, *Foxg1-IRES-Cre; Isl1^{F/F}*, *SBR-Cre; Isl1^{F/F}*, and *Ascl1^{KI/KI}* mice were fully penetrant. The number of independent values in each experiment is as follows: Fig. 1, five independent biological replicates ($n=5$) were used for RNA in situ hybridization; Fig. 2, $n=5$ for immunohistochemistry; Fig. 3, $n=3$ for real-time RT-PCR, $n=3$ for ISH, $n=3$

for explant culture; Fig. 4, $n=3$ for immunohistochemistry, $n=5$ for Neurovue tracing; Fig. 5, $n=3$ for RNA *in situ* hybridization; Fig. 6, $n=5$ for RNA in situ hybridization (A), $n=4$ for RNA in situ hybridization (E), $n=3$ for immunohistochemistry, $n=5$ for Neurovue tracing; Fig. 7, $n=3$ for *Isl1*, *Dlx1*, and *Pax6* immunostaining in control and *Ascl1^{KI/KI}* cells, $n=5$ for neurite outgrowth in control and *Ascl1^{KI/KI}* cells, $n=4$ for *Dlx1* and *Pax6* immunostaining in transfected *Ascl1^{KI/KI}* cells, $n=5$ for neurite outgrowth in transfected *Ascl1^{KI/KI}* cells. Relevant information for each experiment, including statistical tests and p values, is included in the legend corresponding to each figure. In all cases, $p \leq 0.05$ was considered to indicate statistical significance.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00018-024-05523-6>.

Acknowledgements Not applicable.

Author contributions Conceived the project: YJ. Designed the experiments: QN, YJ. Performed experiments: QN, HT. Analyzed the data: QN, HT, YJ. Wrote the paper: YJ. Reviewed the paper: QN, HT, YJ.

Funding This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korea Ministry of Science and ICT (No. 2022R1F1A1064555).

Data availability All data generated or analyzed during this study are included in the manuscript and supporting files.

Declarations

Competing interests There are no competing interests.

Ethics approval All animal procedures were carried out in accordance with the guidelines and protocols approved by the Kyung Hee University Institutional Animal Care and Use Committee.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Nair A, Treiber JM, Shukla DK et al (2013) Impaired thalamocortical connectivity in autism spectrum disorder: a study of functional and anatomical connectivity. *Brain* 136:1942–1955. <https://doi.org/10.1093/brain/awt079>
- Krol A, Wimmer RD, Halassa MM, Feng G (2018) Thalamic reticular dysfunction as a Circuit Endophenotype in Neurodevelopmental disorders. *Neuron* 98:282–295. <https://doi.org/10.1016/j.neuron.2018.03.021>
- Steuillet P, Cabungcal JH, Bukhari SA et al (2018) The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress. *Mol Psychiatry* 23:2057–2065. <https://doi.org/10.1038/mp.2017.230>
- Sheffield JM, Huang AS, Rogers BP et al (2020) Thalamocortical anatomical connectivity in schizophrenia and psychotic bipolar disorder. *Schizophr Bull* 46:1062–1071. <https://doi.org/10.1093/schbul/sbaa022>
- Pinault D (2004) The thalamic reticular nucleus: structure, function and concept. *Brain Res Rev* 46:1–31. <https://doi.org/10.1016/j.brainresrev.2004.04.008>
- Jones E (2007) *The Thalamus*, 2nd edn. Cambridge University Press, Cambridge
- Sherman SM, Guillery RW (2002) The role of the thalamus in the flow of information to the cortex. *Philos Trans R Soc B Biol Sci* 357:1695–1708. <https://doi.org/10.1098/rstb.2002.1161>
- McAlonan K, Cavanaugh J, Wurtz RH (2006) Attentional modulation of thalamic reticular neurons. *J Neurosci* 26:4444–4450. <https://doi.org/10.1523/JNEUROSCI.5602-05.2006>
- Halassa MM, Chen Z, Wimmer RD et al (2014) State-dependent architecture of thalamic reticular subnetworks. *Cell* 158:808–821. <https://doi.org/10.1016/j.cell.2014.06.025>
- Dong P, Wang H, Shen XF et al (2019) A novel cortico-intrathalamic circuit for flight behavior. *Nat Neurosci* 22:941–949. <https://doi.org/10.1038/s41593-019-0391-6>
- Saletin JM, Coon WG, Carskadon MA (2017) Stage 2 Sleep EEG Sigma Activity and Motor Learning in Childhood ADHD: a pilot study. *J Clin Child Adolesc Psychol* 46:188–197. <https://doi.org/10.1080/15374416.2016.1157756>
- Puelles L, Rubenstein JLR (2003) Forebrain gene expression domains and the evolving prosomeric model. *Trends Neurosci* 26:469–476. [https://doi.org/10.1016/S0166-2236\(03\)00234-0](https://doi.org/10.1016/S0166-2236(03)00234-0)
- Halassa MM, Acsády L (2016) Thalamic inhibition: diverse sources, diverse scales. *Trends Neurosci* 39:680–693. <https://doi.org/10.1016/j.tins.2016.08.001>
- Crabtree JW (2018) Functional diversity of thalamic reticular subnetworks. *Front Syst Neurosci* 12:1–18. <https://doi.org/10.3389/fnsys.2018.00041>
- Li Y, Lopez-Huerta VG, Adiconis X et al (2020) Distinct subnetworks of the thalamic reticular nucleus. *Nature* 583:819–824. <https://doi.org/10.1038/s41586-020-2504-5>
- Kiecker C, Lumsden A (2004) Hedgehog signaling from the ZLI regulates diencephalic regional identity. *Nat Neurosci* 7:1242–1249. <https://doi.org/10.1038/nn1338>
- Bluske KK, Vue TY, Kawakami Y et al (2012) β -Catenin signaling specifies progenitor cell identity in parallel with *shh* signaling in the developing mammalian thalamus. *Development* 139:2692–2702. <https://doi.org/10.1242/dev.072314>
- Hagemann AIH, Scholpp S (2012) The tale of the three brothers - *shh*, *wnt*, and *Fgf* during development of the thalamus. *Front Neurosci* 6:1–9. <https://doi.org/10.3389/fnins.2012.00076>
- Kobayashi D, Kobayashi M, Matsumoto K et al (2002) Early subdivisions in the neural plate define distinct competence for

- inductive signals. *Development* 129:83–93. <https://doi.org/10.1242/dev.129.1.83>
20. Hirata T, Nakazawa M, Muraoka O et al (2006) Zinc-finger genes *Fez* and *Fez-like* function in the establishment of diencephalon subdivisions. *Development* 133:3993–4004. <https://doi.org/10.1242/dev.02585>
 21. Scholpp S, Foucher I, Staudt N et al (2007) *Otx11*, *Otx2* and *Irx1b* establish and position the ZLI in the diencephalon. *Development* 134:3167–3176. <https://doi.org/10.1242/dev.001461>
 22. Scholpp S, Lumsden A (2010) Building a bridal chamber: development of the thalamus. *Trends Neurosci* 33:373–380. <https://doi.org/10.1016/j.tins.2010.05.003>
 23. Ono K, Clavairoly A, Nomura T et al (2014) Development of the prethalamus is crucial for thalamocortical projection formation and is regulated by *Olig2*. *Dev* 141:2075–2084. <https://doi.org/10.1242/dev.097790>
 24. Pfaff SL, Mendelsohn M, Stewart CL et al (1996) Requirement for LIM homeobox gene *Isl1* in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. *Cell* 84:309–320. [https://doi.org/10.1016/S0092-8674\(00\)80985-X](https://doi.org/10.1016/S0092-8674(00)80985-X)
 25. Elshatory Y, Everhart D, Deng M et al (2007) *Islet-1* controls the differentiation of retinal bipolar and cholinergic amacrine cells. *J Neurosci* 27:12707–12720. <https://doi.org/10.1523/JNEUROSCI.3951-07.2007>
 26. Gay F, Anglade I, Gong Z, Salbert G (2000) The LIM/Homeodomain Protein *Islet-1* modulates estrogen receptor functions. *Mol Endocrinol* 14:1627–1648. <https://doi.org/10.1210/mend.14.10.0538>
 27. Nasif S, De Souza FSJ, González LE et al (2015) *Islet 1* specifies the identity of hypothalamic melanocortin neurons and is critical for normal food intake and adiposity in adulthood. *Proc Natl Acad Sci U S A* 112:E1861–E1870. <https://doi.org/10.1073/pnas.1500672112>
 28. Ehrman LA, Mu X, Waclaw RR et al (2013) The LIM homeobox gene *Isl1* is required for the correct development of the striatonigral pathway in the mouse. *Proc Natl Acad Sci U S A* 110. <https://doi.org/10.1073/pnas.1308275110>
 29. Lu K-M, Evans SM, Hirano S, Liu F-C (2013) Dual role for *Islet-1* in promoting striatonigral and repressing striatopallidal genetic programs to specify striatonigral cell identity. *Proc Natl Acad Sci* 111. <https://doi.org/10.1073/pnas.1319138111>
 30. Ehrman JM, Merchan-Sala P, Ehrman LA et al (2022) Formation of the Mouse Internal Capsule and Cerebral Peduncle: a pioneering role for Striatonigral axons as revealed in *Isl1* conditional mutants. *J Neurosci* 42:3344–3364. <https://doi.org/10.1523/JNEUROSCI.2291-21.2022>
 31. Guillemot F, Hassan BA (2017) Beyond proneural: emerging functions and regulations of proneural proteins. *Curr Opin Neurobiol* 42:93–101. <https://doi.org/10.1016/j.conb.2016.11.011>
 32. Parras CM, Schuurmans C, Scardigli R et al (2002) Divergent functions of the proneural genes *Mash1* and *Ngn2* in the specification of neuronal subtype identity. *Genes Dev* 16:324–338. <https://doi.org/10.1101/gad.940902>
 33. Li S, Misra K, Matise MP, Xiang M (2005) *Foxn4* acts synergistically with *Mash1* to specify subtype identity of V2 interneurons in the spinal cord. *Proc Natl Acad Sci U S A* 102:10688–10693. <https://doi.org/10.1073/pnas.0504799102>
 34. Aslanpour S, Rosin JM, Balakrishnan A et al (2020) *Ascl1* is required to specify a subset of ventromedial hypothalamic neurons. *Development* 147:1–15. <https://doi.org/10.1242/dev.180067>
 35. Horton S, Meredith A, Richardson JA, Johnson JE (1999) Correct coordination of neuronal differentiation events in ventral forebrain requires the bHLH factor *MASH1*. *Mol Cell Neurosci* 14:355–369. <https://doi.org/10.1006/mcne.1999.0791>
 36. Casarosa S, Fode C, Guillemot F (1999) *Mash1* regulates neurogenesis in the ventral telencephalon. *Development* 126:525–534. <https://doi.org/10.1242/dev.126.3.525>
 37. Tuttle R, Nakagawa Y, Johnson JE, O'Leary DDM (1999) Defects in thalamocortical axon pathfinding correlate with altered cell domains in *Mash-1*-deficient mice. *Development* 126:1903–1916. <https://doi.org/10.1242/dev.126.9.1903>
 38. Sun Y, Dykes IM, Liang X et al (2008) A central role for *Islet1* in sensory neuron development linking sensory and spinal gene regulatory programs. *Nat Neurosci* 11:1283–1293. <https://doi.org/10.1038/nn.2209>
 39. Monory K, Massa F, Egertová M et al (2006) The Endocannabinoid System Controls Key Epileptogenic circuits in the Hippocampus. *Neuron* 51:455–466. <https://doi.org/10.1016/j.neuron.2006.07.006>
 40. Kitamura K, Miura H, Yanazawa M et al (1997) Expression patterns of *Brx1* (*Rieg* gene), sonic hedgehog, *Nkx2.2*, *Dlx1* and *Arx* during zona limitans intrathalamica and embryonic ventral lateral geniculate nuclear formation. *Mech Dev* 67:83–96. [https://doi.org/10.1016/S0925-4773\(97\)00110-X](https://doi.org/10.1016/S0925-4773(97)00110-X)
 41. Nakagawa Y, O'Leary DDM (2001) Combinatorial expression patterns of LIM-homeodomain and other regulatory genes parcellate developing thalamus. *J Neurosci* 21:2711–2725. <https://doi.org/10.1523/jneurosci.21-08-02711.2001>
 42. Caballero IM, Manuel MN, Molinek M et al (2014) Cell-Autonomous repression of *shh* by transcription factor *Pax6* regulates Diencephalic Patterning by Controlling the Central Diencephalic Organizer. *Cell Rep* 8:1405–1418. <https://doi.org/10.1016/j.celrep.2014.07.051>
 43. Chen L, Guo Q, Li JYH (2009) Transcription factor *Gbx2* acts cell-nonautonomously to regulate the formation of lineage-restriction boundaries of the thalamus. *Development* 136:1317–1326. <https://doi.org/10.1242/dev.030510>
 44. Chatterjee M, Li K, Chen L et al (2012) *Gbx2* regulates thalamocortical axon guidance by modifying the LIM and *Robo* codes. *Dev* 139:4633–4643. <https://doi.org/10.1242/dev.086991>
 45. Deck M, Lokmane L, Chauvet S et al (2013) Pathfinding of Corticothalamic Axons Relies on a rendezvous with thalamic projections. *Neuron* 77:472–484. <https://doi.org/10.1016/j.neuron.2012.11.031>
 46. Kawaguchi D, Sahara S, Zembrzycki A, O'Leary DDM (2016) Generation and analysis of an improved *Foxg1-IRES-Cre* driver mouse line. *Dev Biol* 412:139–147. <https://doi.org/10.1016/j.ydbio.2016.02.011>
 47. Marcos-Mondéjar P, Peregrín S, Li JY et al (2012) The *Lhx2* transcription factor controls thalamocortical axonal guidance by specific regulation of *Robo1* and *Robo2* receptors. *J Neurosci* 32:4372–4385. <https://doi.org/10.1523/JNEUROSCI.5851-11.2012>
 48. Seibt J, Schuurmans C, Gradwohl G et al (2003) *Neurogenin2* specifies the connectivity of thalamic neurons by controlling axon responsiveness to intermediate target cues. *Neuron* 39:439–452. [https://doi.org/10.1016/S0896-6273\(03\)00435-5](https://doi.org/10.1016/S0896-6273(03)00435-5)
 49. Lee M, Yoon J, Song H et al (2017) *Tcf7l2* plays crucial roles in forebrain development through regulation of thalamic and habenular neuron identity and connectivity. *Dev Biol* 424:62–76. <https://doi.org/10.1016/j.ydbio.2017.02.010>
 50. Quintana-Urzaínqui I, Hernández-Malmierca P, Clegg JM et al (2020) The role of the diencephalon in the guidance of thalamocortical axons in mice. *Dev* 147. <https://doi.org/10.1242/dev.184523>
 51. Mitrofanis J, Baker GE (1993) Development of the thalamic reticular and perireticular nuclei in rats and their relationship to the course of growing corticofugal and corticopetal axons. *J Comp Neurol* 338:575–587. <https://doi.org/10.1002/cne.903380407>

52. Mitrofanis J, Guillery RW (1993) New views of the thalamic reticular nucleus in the adult and the developing brain. *Trends Neurosci* 16:240–245. [https://doi.org/10.1016/0166-2236\(93\)90163-G](https://doi.org/10.1016/0166-2236(93)90163-G)
53. López-Bendito G, Molnár Z (2003) Thalamocortical development: how are we going to get there? *Nat Rev Neurosci* 4:276–289. <https://doi.org/10.1038/nrn1075>
54. Lee B, Song H, Rizzoti K et al (2013) Genomic code for Sox2 binding uncovers its regulatory role in Six3 activation in the forebrain. *Dev Biol* 381:491–501. <https://doi.org/10.1016/j.ydbio.2013.06.016>
55. Leung CT, Coulombe PA, Reed RR (2007) Contribution of olfactory neural stem cells to tissue maintenance and regeneration. *Nat Neurosci* 10:720–726. <https://doi.org/10.1038/nn1882>
56. Thaler JP, Lee SK, Jurata LW et al (2002) LIM factor Lhx3 contributes to the specification of motor neuron and interneuron identity through cell-type-specific protein-protein interactions. *Cell* 110:237–249. [https://doi.org/10.1016/S0092-8674\(02\)00823-1](https://doi.org/10.1016/S0092-8674(02)00823-1)
57. Cho H-H, Cargnin F, Kim Y et al (2014) Is11 directly controls a cholinergic neuronal identity in the developing forebrain and spinal cord by forming cell type-specific complexes. *PLoS Genet* 10:e1004280. <https://doi.org/10.1371/journal.pgen.1004280>
58. Garel S, Yun K, Grosschedl R, Rubenstein JLR (2002) The early topography of thalamocortical projections is shifted in *Ebf1* and *Dlx2* mutant mice. *Development* 129:5621–5634. <https://doi.org/10.1242/dev.00166>
59. Kania A, Klein R (2016) Mechanisms of ephrin-eph signalling in development, physiology and disease. *Nat Rev Mol Cell Biol* 17:240–256. <https://doi.org/10.1038/nrm.2015.16>
60. Gao PP, Yue Y, Zhang JH et al (1998) Regulation of thalamic neurite outgrowth by the eph ligand ephrin-A5: implications in the development of thalamocortical projections. *Proc Natl Acad Sci U S A* 95:5329–5334. <https://doi.org/10.1073/pnas.95.9.5329>
61. Vanderhaeghen P, Lu Q, Prakash N et al (2000) A mapping label required for normal scale of body representation in the cortex. *Nat Neurosci* 3:358–365. <https://doi.org/10.1038/73929>
62. Vasconcelos FF, Castro DS (2014) Transcriptional control of vertebrate neurogenesis by the proneural factor *ascl1*. *Front Cell Neurosci* 8:1–6. <https://doi.org/10.3389/fncel.2014.00412>
63. Peltopuro P, Kala K, Partanen J (2010) Distinct requirements for *Ascl1* in subpopulations of midbrain GABAergic neurons. *Dev Biol* 343:63–70. <https://doi.org/10.1016/j.ydbio.2010.04.015>
64. Madisen L, Zwingman TA, Sunkin SM et al (2010) A robust and high-throughput cre reporting and characterization system for the whole mouse brain. *Nat Neurosci* 13:133–140. <https://doi.org/10.1038/nn.2467>
65. Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682. <https://doi.org/10.1038/nmeth.2019>
66. Brose K, Bland KS, Wang KH et al (1999) Slit Proteins Bind Robo Receptors and have an evolutionarily conserved Role in Repulsive Axon Guidance. *Cell* 96:795–806. [https://doi.org/10.1016/S0092-8674\(00\)80590-5](https://doi.org/10.1016/S0092-8674(00)80590-5)
67. Shaner NC, Campbell RE, Steinbach PA et al (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from *Discosoma* sp. red fluorescent protein. *Nat Biotechnol* 22:1567–1572. <https://doi.org/10.1038/nbt1037>
68. Pool M, Thiemann J, Bar-Or A, Fournier AE (2008) NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. *J Neurosci Methods* 168:134–139. <https://doi.org/10.1016/j.jneumeth.2007.08.029>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.